GlassScriptPhysician profile
Soledad Reyes
NPI 1003431172
$6,792.74
in general payments reported to CMS, 2019-2025
33 companies · $1,023 in 2025
The $1,023 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $907 · 2022: $2,389 · 2023: $1,189 · 2024: $1,285 · 2025: $1,023.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,497.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,497.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,335.23 | 2021-2025 | Wegovy |
| Incyte Corporation | $596.84 | 2022-2024 | Opzelura |
| Abbvie INC. | $506.04 | 2021-2025 | |
| Amgen INC. | $496.86 | 2023-2025 | Repatha, Otezla |
| Intercept Pharmaceuticals, INC. | $350.61 | 2021-2022 | |
| Ardelyx, INC. | $273.37 | 2023-2025 | Ibsrela |
| Gilead Sciences, INC. | $246.88 | 2022-2023 | Vemlidy |
| Ultragenyx Pharmaceutical INC. | $220.53 | 2022 | |
| Lilly USA, LLC | $160.48 | 2022-2023 | Mounjaro |
| Dexcom, INC. | $159.04 | 2024-2025 | Dexcom Stelo Glucose Biosensor, Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Ipsen Biopharmaceuticals, INC | $146.20 | 2024 | Iqirvo |
| Abbott Laboratories | $142.97 | 2022 | |
| Neurocrine Biosciences, INC. | $139.77 | 2024 | Ingrezza |
| Medtronic, INC. | $130.06 | 2022 | |
| Phathom Pharmaceuticals, INC. | $125.00 | 2024 | Voquezna |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $125.00 | 2022 | |
| Fresenius Kabi USA, LLC | $125.00 | 2024 | Idacio |
| Redhill Biopharma INC. | $124.99 | 2022 | |
| Nestle Healthcare Nutrition INC. | $123.81 | 2021 | |
| Aimmune Therapeutics, INC. | $123.63 | 2024 | |
| Eisai INC. | $122.06 | 2025 | |
| Mayne Pharma Commercial LLC | $121.83 | 2024 | |
| Madrigal Pharmaceuticals | $121.06 | 2025 | Rezdiffra |
| Dynavax Technologies Corporation | $116.64 | 2024 | Heplisav-B |
| Acadia Pharmaceuticals INC | $113.47 | 2025 | Nuplazid |
| Ironwood Pharmaceuticals, INC | $101.55 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $99.83 | 2023 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $98.12 | 2022 | |
| Neurelis, INC. | $94.93 | 2022 | |
| Scynexis, INC. | $76.66 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $30.30 | 2022 | |
| Exact Sciences Corporation | $23.09 | 2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $20.89 | 2023 | Trelegy Ellipta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Soledad Reyes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.